Tablet not actual size.

Typical characteristics of migraine are headache of unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity and association with nausea and/or photophobia and phonophobia.3 AQUIPTA® is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.1 ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance; website: www.hpra.ie


References:

1. AQUIPTA® Summary of Product Characteristics (Ireland). (Accessed: December 2024), available at www.medicines.ie. 2. Morena-Ajona D, et al. J Clin Med. 2022;11(6):1656. 3. Ferrari MD, et al. Nat Rev Dis Primers. 2022;8(1):2.

AQUIPTA®

MIGRAINE PREVENTION THAT:

HAS COMPREHENSIVE EFFICACY*1-5

Indicated for patients with episodic or chronic migraine1

Effective†1,2,5 and rapid‡3 monthly migraine day reduction that was sustained for up to 1 year in patients with episodic migraine§4

OFFERS THE POSSIBILITY OF DAYS OF MIGRAINE FREEDOM¶4,6,7

0 migraine attacks in 48.4% of episodic AQUIPTA® 60 mg-treated patients in Weeks 49-52§4

IS GENERALLY WELL TOLERATED*2,5

With adverse reactions leading to discontinuation similar in the placebo and AQUIPTA® 60 mg arms*2,5

IS SIMPLE TO TAKE

One tablet, once a day1

*AQUIPTA® was evaluated for the prophylaxis of migraine in two pivotal studies. The episodic migraine study (ADVANCE) enrolled patients who met ICHD criteria for a diagnosis of migraine with or without aura. The chronic migraine study (PROGRESS) enrolled patients who met ICHD criteria for chronic migraine.1 †Effectiveness was based on the primary endpoint of reduction in mean monthly migraine days from baseline across 12 weeks in the ADVANCE and PROGRESS studies.1,2,5 ‡Rapid efficacy based on exploratory endpoints in the ADVANCE study which included the proportion of participants with a migraine on each day during the first week of treatment.3 §Data from an open-label safety study that randomised 744 patients 5:2 to receive either AQUIPTA® 60 mg (N=546) or standard of care migraine prevention medication (n=198). Efficacy endpoints for long-term efficacy evaluation included changes from baseline in least squares mean monthly migraine days and were not classified as primary, secondary or additional endpoints.4 In an open-label extension with observed data, there is potential for enrichment of the long-term data as those who remain in the study generally fare better than those who discontinue. ¶Migraine freedom defined as 0 attacks in a defined period.1,2


References:

1. AQUIPTA® Summary of Product Characteristics (Ireland). (Accessed: December 2024), available on www.medicines.ie. 2. Ailani J, et al. N Engl J Med. 2021;385:695–706. 3. Schwedt TJ, et al. Cephalalgia. 2022;42(1):3–11. 4. Ashina M, et al. Headache. 2023;63(1):79–88. 5. Pozo-Rosich P, et al. Lancet. 2023;402(10404):775–785. (with Supplementary Appendix). 6. Lipton RB, et al. JAMA Netw Open. 2022;5(6):e2215499. 7. Lipton RB, et al. Presented at the Migraine Trust International Symposium (MTIS) 2022, 8–11 September; London, UK.